Novartis Signs Development Deal With Cell Therapeutics For Xyotax
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis and CTI will develop and commercialize poliglumex paclitaxel, currently in Phase III for non-small cell lung cancer in women.